Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Status:
Not yet recruiting
Trial end date:
2027-09-29
Target enrollment:
Participant gender:
Summary
The study will measure the safety, tolerability, and efficacy with acalabrutinib in
combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse
large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line
chemoimmunotherapy treatments.